国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

美國B(niǎo)IND Therapeutics  
 BIND的生物科技是一家生物制藥公司，開(kāi)發(fā)治療深刻改善集中在靶組織的藥物，同時(shí)盡量減少系統性風(fēng)險患者的生活能有針對性的納米粒子。我們的技術(shù)平臺，提供了獨特的能力，為他們的特定應用優(yōu)化治療精確，重復性納米我們。
　BIND公司制藥科學(xué)副總裁杰夫·哈凱基表示，這是首個(gè)進(jìn)入臨床實(shí)踐的可遞送化療藥物的靶向型納米粒子。接下來(lái)，公司會(huì )將其發(fā)展成一個(gè)平臺，用于治療心血管疾病、各類(lèi)炎癥，甚至傳染性疾病。


BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.